Celanese Announces Leadership Transition

Celanese Announces Leadership Transition

Scott Richardson to Become Chief Executive Officer and Join the Board of Directors

Edward Galante to Become Chair of the Celanese Board

Lori Ryerkerk to Step Down from the Board and Her Roles as CEO and President at the End of the Year

DALLAS–(BUSINESS WIRE)–
Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced that Scott Richardson, currently Celanese’s Chief Operating Officer, has been appointed Chief Executive Officer and will join the Company’s Board of Directors, effective January 1, 2025. Richardson will succeed Lori Ryerkerk, who is stepping down as Chairman, CEO and director of Celanese at the end of the year. Celanese has elected Edward Galante, an independent director on Celanese’s Board since 2013, as Chair of the Board, effective upon Ryerkerk’s departure.

Over his two decades of service at Celanese, Scott Richardson has served in a number of key management roles, including Chief Operating Officer, Chief Financial Officer and leadership positions overseeing Celanese’s leading global Engineered Materials (EM) and Acetyl Chain (AC) businesses. Richardson was intimately involved in creating and implementing the EM and AC operating models that work together as a strategic pair to create value.

“It is an incredible honor to be named CEO-elect of Celanese, and I am grateful to our Board of Directors for entrusting me with this responsibility,” said Richardson. “Celanese is known for tenacious execution, even during difficult times, and I am confident we have all the critical components to create value for our shareholders, customers, employees and partners. I am fully committed to driving the changes needed in light of today’s challenges, including our relentless efforts to improve our cost structure and drive cash generation. By executing our action plan and controlling what we can control, we are working to position Celanese to capitalize on its significant upside potential, resilient free cash flow and long-term value creation.”

“Coming out of retirement to lead Celanese since 2019 as CEO has been the true highlight of my career, and I’m proud of what we’ve achieved together,” said Ryerkerk. “Scott is a proven executive who brings deep expertise across the Company’s business and new perspectives to the CEO role. I look forward to seeing what he accomplishes as he works with the team to build an even stronger Celanese.”

“The Board’s appointment of Scott represents the culmination of a deliberate and thoughtful succession planning process, and we are pleased to have an executive of Scott’s caliber,” said Kim Rucker, Lead Independent Director of Celanese’s Board of Directors. “The Board is looking forward to the long-term success of Celanese under Scott’s direction.”

Rucker continued, “On behalf of the Board, I also want to thank Lori for her leadership and significant contributions over the last five years. With Lori at the helm, Celanese has navigated challenging macro environments while strengthening its competitive position. We wish her all the best in her next chapter.”

About Scott A. Richardson

Richardson was named Executive Vice President and Chief Operating Officer for Celanese Corporation on November 8, 2023, after serving as EVP & Chief Financial Officer since February 2018, and prior to this was senior vice president of the Engineered Materials business since December 2015, where he had global responsibility for strategy, product and business management, planning and portfolio development, and pipeline management. Previously, Richardson served as vice president and general manager of the Acetyl Chain since 2011.

Richardson has progressed through several Celanese roles including global commercial director, Acetyls; manager of Investor Relations; business analysis manager, Acetyls; and business line controller, Polyols and Solvents. He joined Celanese in 2005.

Before joining Celanese, Richardson held various finance, operational and leadership roles at American Airlines. He earned a Bachelor of Arts degree in Accounting from Westminster College, and a Master of Business Administration from Texas Christian University.

About Edward G. Galante

Ed Galante was elected to the Celanese Board of Directors in 2012. He was previously Senior Vice President and Member of the management committee of Exxon Mobil Corporation, an international oil and gas company (2001 – 2006), and Executive Vice President of ExxonMobil Chemical Company (1999 – 2001). Prior to that, he held various management positions of increasing responsibility over more than 30 years with the company.

He serves as an Independent Director at Clean Harbors, Inc., a leading provider of environmental and industrial services; at Marathon Petroleum Corporation, a leading, integrated, downstream energy company; and former Independent Director at Linde plc, a leading industrial gas and engineering company.

Galante earned a B.S. in civil engineering from Northeastern University.

About Celanese

Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We are committed to sustainability by responsibly managing the materials we create for their entire lifecycle and are growing our portfolio of sustainable products to meet increasing customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

Forward-Looking Statements

The information set forth in this Press Release contains certain “forward-looking statements,” which include information concerning the Company’s current beliefs, understanding and expectations regarding the Company’s plans, objectives, goals, strategies, financial performance and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. Numerous factors, many of which are beyond the Company’s control could cause actual results to differ materially from those expressed as forward-looking statements, including those factors addressed in the Company’s November 4, 2024 earnings press release furnished as Exhibit 99.1 to the Company’s Items 2.02 and 9.01 Form 8-K dated November 4, 2024. Any forward-looking statement speaks only as of the date it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date the statement is made.

Celanese Contacts:

Investor Relations

Bill Cunningham

Phone: +1 302 999 6410

[email protected]

Media – U.S.

Brian Bianco

Phone: +1 972 443 4400

[email protected]

Media – Europe

Petra Czugler

Phone: +49 69 45009 1206

[email protected]

KEYWORDS: Texas

INDUSTRY KEYWORDS: Chemicals/Plastics

MEDIA:

Logo
Logo

Compass Diversified to Host Investor Day on January 16, 2025, in New York City

WESTPORT, Conn., Dec. 09, 2024 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, today announced that it will host its investor day on Thursday, January 16, 2025, at 9:30am ET at Convene’s One Liberty Plaza location in New York City.

The event will include a presentation by CODI’s executive management team followed by a Q&A session, as well as a panel discussion moderated by CODI CEO, Elias Sabo with the CEOs of 5.11 Tactical, PrimaLoft, and Altor Solutions. A summary agenda is provided below. All times in EST.

• 9:30am – 10:00am: Participant check-in and continental breakfast
• 10:00am – 11:30pm: Compass Diversified presentation and Q&A session
• 11:30am – 12:30pm: Moderated panel discussion
• 12:30pm – 1:30pm: Lunch and self-guided, interactive tour of CODI’s 10 businesses
   

To attend the event in-person, please RSVP to CODI’s investor relations firm, Gateway Group, at CODI@gateway-grp.com.

To register your virtual attendance or view an archived replay, please click the following link: CODI January 2025 Investor Day.

Please allow extra time prior to the start of the event to download any necessary software that may be needed to view the webcast.

About Compass Diversified

Since its IPO in 2006, CODI has consistently executed its strategy of owning and managing a diverse set of highly defensible, middle-market businesses across the industrial, branded consumer and healthcare sectors. The Company leverages its permanent capital base, long-term disciplined approach, and actionable expertise to maintain controlling ownership interests in each of its subsidiaries, maximizing its ability to impact long-term cash flow generation and value creation. The Company provides both debt and equity capital for its subsidiaries, contributing to their financial and operating flexibility. CODI utilizes the cash flows generated by its subsidiaries to invest in the long-term growth of the Company and has consistently generated strong returns through its culture of transparency, alignment and accountability. For more information, please visit compassdiversified.com.

Investor Relations

Compass Diversified
[email protected]

Gateway Group
Cody Slach
949.574.3860
[email protected]

Media Relations

Compass Diversified
[email protected]

The IGB Group
Leon Berman
212.477.8438
[email protected]



Tim Keating Joins AMD as Senior Vice President, Government Relations and Regulatory Affairs

SANTA CLARA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced that Tim Keating has joined the company as senior vice president, Government Relations and Regulatory Affairs, effective today.

“Tim is a strong addition to lead our government relations team,” said Ava Hahn, AMD senior vice president, general counsel and corporate secretary. “As high-performance and AI chips play an increasingly larger role in our daily lives over the coming years, Tim’s extensive public policy expertise and deep understanding of regulatory landscapes will play a critical role expanding our engagements with key stakeholders.”

Keating has decades of experience, including more than 14 years at Boeing as executive vice president, Government Relations. Before Boeing, he was the senior vice president of Global Government Operations at Honeywell International and served as special assistant to the President of the United States and as staff director for White House Legislative Affairs. He also held several positions with the U.S. House of Representatives. Keating received a bachelor’s degree in political science from the University of Scranton and an honorary doctorate of business administration from the University of South Carolina.

About AMD

For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn and X pages. 

AMD, the AMD Arrow logo and combinations thereof, are trademarks of Advanced Micro Devices, Inc.

Contact:

Brandi Martina

AMD Communications
(512) 705-1720
[email protected]

Mitch Haws

AMD Investor Relations
512-944-0790
[email protected]



NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

  • Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial
  • 23 months median Overall Survival from date of diagnosis was observed in 22 patients with locally advanced or borderline resectable pancreatic cancer
  • US FDA approved protocol amendment to launch new cohort evaluating RT-activated NBTXR3 combined with standard-of-care concurrent chemotherapy and recruitment is ongoing
  • Full data from the completed dose escalation and dose expansion cohorts to be presented at a medical congress in 1H 2025

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy(“RT”)-activated NBTXR3 (JNJ-1900) for patients with locally advanced pancreatic cancer (“LAPC”) or borderline resectable pancreatic cancer (“BRPC”). The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”).

Patients with LAPC or BRPC often receive initial treatment with cytotoxic chemotherapy followed by RT +/- concurrent or maintenance chemotherapy.

This Phase 1 study was designed to evaluate the safety, feasibility, and early signs of efficacy of RT-activated NBTXR3 for patients with LAPC or BRPC after initial treatment with cytotoxic chemotherapy, in comparison to the historical data in patients who received RT +/- concurrent or maintenance chemotherapy after initial treatment with cytotoxic chemotherapy.

Investigators observed an mOS of 23 months from the date of diagnosis in 22 patients (20 with LAPC and 2 with BRPC) on the trial that compared favorably with outcomes at MD Anderson where the historical control for mOS in 144 patients treated at the same center was 19.2 months. Investigators concluded that RT-activated NBTXR3 was well tolerated by all patients and that the encouraging oncologic outcomes observed warrant further evaluation in a randomized trial.

Following these encouraging results from the study, MD Anderson submitted and received US FDA clearance for a new, additional study cohort evaluating the combination of NBTXR3 and standard-of-care concurrent chemoradiation. The new cohort has launched, and recruitment is ongoing.

“The results we have observed in this Phase 1 study give us confidence that NBTXR3 could have a significant impact for these patients,” said Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. “We look forward to the data from the new cohort and believe the combination of NBTXR3 and concurrent chemoradiation could produce even more favorable outcomes for patients with locally advanced or borderline resectable pancreatic cancer.”

Nanobiotix expects full results from the completed dose escalation and dose expansion parts of the study to be presented by MD Anderson at a medical congress in 1H 2025.

About NBTXR3

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, in Nanobiotix’ 2024 semi-annual report under the caption “Supplemental Risk Factor” filed with the SEC on Form 6-K and with AMF on September 18 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835
[email protected]
Investor Relations Department

Craig West

SVP, Investor Relations

+1 (617) 583-0211
[email protected]
Media Relations

FR – Ulysse Communication
Laurent Wormser
+ 33 (0)6 13 12 04 04
[email protected]
Global – LifeSci Advisors
Kevin Gardner
+1 (617) 283-2856
[email protected]

Attachment



Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

CHMP opinion now expected in 1Q 2025

No Major Objections outstanding; continue to expect Germany launch in 2Q 2025

PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues.

There are no Major Objections outstanding from the EMA with respect to the full approval of B-VEC.

“We are confident in our ability to address the remaining post-marketing issues, and we believe that this additional exchange with EMA will ultimately maximize benefit and convenience to patients suffering from DEB,” said Suma Krishnan, President of Research and Development at Krystal Biotech.

The Company now anticipates a CHMP opinion in 1Q 2025 while the launch timelines remain unchanged with a commercial launch in Germany still planned for Q2 2025.

About Dystrophic Epidermolysis Bullosa (DEB)

DEB is a rare and severe disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1, which is responsible for the production of the protein type VII collagen (COL7) that forms anchoring fibrils that bind the dermis (inner layer of the skin) to the epidermis (outer layer of the skin). The lack of functional anchoring fibrils in DEB patients leads to extremely fragile skin that blisters and tears from minor friction or trauma. DEB patients suffer from open wounds, which leads to skin infections, fibrosis which can cause fusion of fingers and toes, and ultimately an increased risk of developing an aggressive form of squamous cell carcinoma which, in severe cases, can be fatal.

About B-VEC and VYJUVEK

B-VEC is a non-invasive, redosable gene therapy built to deliver two copies of the COL7A1 gene to treat DEB at the molecular level by providing the patient’s cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. B-VEC was approved by U.S. Food and Drug Agency (FDA) in May 2023 for the treatment of DEB and is marketed and sold in the U.S. under the name VYJUVEK®. For more information on VYJUVEK, see full U.S. Prescribing Information.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

Forward-Looking Statements

This press release contains forward-looking statements, including those regarding the EMA’s review timeline and approval prospects for B-VEC, and the Company’s plans and timeline for its commercial launch of B-VEC in the European Union. Actual outcomes may differ materially based on various factors, including uncertainties associated with regulatory review and marketing approvals and such other important factors as are set forth under the caption “Risk Factors” in the Company’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

CONTACT

Investors and Media:

Stéphane Paquette, PhD
Krystal Biotech
[email protected]



Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee granted David Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz’s employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Verrica, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The option award will have an exercise price equal to the closing price of Verrica’s common stock on December 9, 2024. The option award will vest and become exercisable as to 1/8th of the shares on the date that is six months following Mr. Zawitz’s start date, and 1/48th of the shares each month thereafter on the same day of the month as the start date, subject to Mr. Zawitz’s continuous service with Verrica on such vesting dates. The option award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of a stock option agreement covering the grant.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Kevin Gardner

LifeSci Advisors
[email protected]

Chris Calabrese

LifeSci Advisors
[email protected]



Cencora Closes $1.8 Billion Senior Notes Offering

Cencora Closes $1.8 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–
Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024.

Cencora intends to use the net proceeds from the offering to finance the acquisition of the majority of Retina Consultants of America and related fees and expenses, and for general corporate purposes.

The joint book-running managers for the offering were BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC. Cencora filed a final prospectus supplement and an accompanying prospectus with the SEC in connection with the offering of the Notes. Copies of these materials can be made available by contacting: BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, email: [email protected] or telephone: 1-800-294-1322; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, email: [email protected] or telephone: 1-800-831-9146; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attention: Investment Grade Syndicate Desk, 3rd Floor, telephone collect at 1-212-834-4533; and Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, 608 2nd Avenue South, Suite 1000, Minneapolis, Minnesota 55402, Attention: WFS Customer Service, email: [email protected] or telephone: 1-800-645-3751. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the SEC’s web site at www.sec.gov.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue.

Cencora’s Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,”, “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and elsewhere in that report and other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

Bennett S. Murphy

Senior Vice President, Head of Investor Relations & Treasury

610-727-3693

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Veterinary Pharmaceutical Finance General Health Health Banking Professional Services Health Insurance

MEDIA:

Liberty Broadband Corporation Declares Quarterly Cash Dividend on Series A Cumulative Redeemable Preferred Stock

Liberty Broadband Corporation Declares Quarterly Cash Dividend on Series A Cumulative Redeemable Preferred Stock

ENGLEWOOD, Colo.–(BUSINESS WIRE)–
Liberty Broadband Corporation (Nasdaq: LBRDA, LBRDK, LBRDP) today announced that its Board of Directors declared the regular quarterly cash dividend payable to holders of its Series A Cumulative Redeemable Preferred Stock (the “Preferred Stock”) (Nasdaq: LBRDP). The per share amount of the quarterly cash dividend will be $0.43750001, payable in cash on January 15, 2025 to holders of record of the Preferred Stock at the close of business on December 31, 2024 (the “Record Date”).

About Liberty Broadband Corporation

Liberty Broadband Corporation (Nasdaq: LBRDA, LBRDK, LBRDP) operates and owns interests in a broad range of communications businesses. Liberty Broadband’s principal assets consist of its interest in Charter Communications and its subsidiary GCI. GCI is Alaska’s largest communications provider, providing data, wireless, video, voice and managed services to consumer and business customers throughout Alaska and nationwide. GCI has delivered services over the past 40 years to some of the most remote communities and in some of the most challenging conditions in North America.

Liberty Broadband Corporation

Shane Kleinstein, 720-875-5432

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Data Management Consumer Electronics Technology Telecommunications Mobile/Wireless Internet Carriers and Services

MEDIA:

Logo
Logo

Casey’s Announces Second Quarter Results

Casey’s Announces Second Quarter Results

ANKENY, Iowa–(BUSINESS WIRE)–
Casey’s General Stores, Inc. (“Casey’s” or the “Company”) (Nasdaq: CASY) one of the leading convenience store chains in the United States, today announced financial results for the three and six months ended October 31, 2024.

Second Quarter Key Highlights

  • Diluted EPS of $4.85, up 14% from the same period a year ago. Net income was $181 million, up 14%, and EBITDA1 was $349 million, up 14%, from the same period a year ago.

  • Inside same-store sales increased 4.0% compared to prior year, and 7.1% on a two-year stack basis, with an inside margin of 42.2%. Total inside gross profit increased 12.0% to $619.7 million compared to the prior year.

  • Same-store fuel gallons were down 0.6% compared to prior year with a fuel margin of 40.2 cents per gallon. Total fuel gross profit increased 1.1% to $312.3 million compared to the prior year.

  • Same-store operating expenses excluding credit card fees were up 2.3%, favorably impacted by a 1% reduction in same-store labor hours.

  • Subsequent to quarter end, on November 1, 2024, Casey’s closed the previously announced Fikes Wholesale (“Fikes”) transaction, acquiring 198 CEFCO Convenience Stores.

“Casey’s delivered a strong second quarter highlighted by robust inside gross profit growth,” said Darren Rebelez, Board Chair, President and CEO. “Inside same-store sales were driven by the prepared food and dispensed beverage category, with hot sandwiches and cold dispensed beverage performing exceptionally well. Our fuel team continues to balance volume and margin as they achieved over 40 cents per gallon fuel margin while outpacing the relevant geographic market in same-store fuel gallons. The operations team continues to focus on efficiency while serving our guests, as we reduced same-store labor hours for the tenth consecutive quarter. Finally, we are excited to have closed on the Fikes acquisition and we want to welcome the team to the Casey’s family.”

Earnings

 

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Net income (in thousands)

$

180,918

 

$

158,782

 

$

361,116

 

$

328,019

Diluted earnings per share

$

4.85

 

$

4.24

 

$

9.68

 

$

8.76

EBITDA (in thousands)

$

348,880

 

$

305,858

 

$

694,662

 

$

622,757

For the quarter, net income, diluted EPS, and EBITDA were up compared to the same period a year ago primarily due to higher inside and fuel gross profit, partially offset by higher operating expenses primarily due to operating 93 additional stores.

_________________

1 EBITDA is reconciled to net income below.

Inside

 

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Inside sales (in thousands)

$

1,467,524

 

 

$

1,346,911

 

 

$

2,941,631

 

 

$

2,716,660

 

Inside same-store sales

 

4.0

%

 

 

2.9

%

 

 

3.1

%

 

 

4.2

%

Grocery and general merchandise same-store sales

 

3.6

%

 

 

1.7

%

 

 

2.5

%

 

 

3.5

%

Prepared food and dispensed beverage same-store sales

 

5.2

%

 

 

6.1

%

 

 

4.7

%

 

 

5.9

%

Inside gross profit (in thousands)

$

619,651

 

 

$

553,264

 

 

$

1,233,973

 

 

$

1,109,698

 

Inside margin

 

42.2

%

 

 

41.1

%

 

 

41.9

%

 

 

40.8

%

Grocery and general merchandise margin

 

35.6

%

 

 

34.0

%

 

 

35.5

%

 

 

34.0

%

Prepared food and dispensed beverage margin

 

58.7

%

 

 

59.0

%

 

 

58.5

%

 

 

58.6

%

Total inside sales were up 9.0% for the quarter driven by strong performance in the prepared food and dispensed beverage category, including hot sandwiches and dispensed beverage as well as non-alcoholic and alcoholic beverages in the grocery and general merchandise category. Inside margin was up 110 basis points compared to the same quarter a year ago, driven primarily by product mix and asset protection initiatives.

Fuel2

 

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Fuel gallons sold (in thousands)

 

775,914

 

 

 

730,439

 

 

 

1,548,450

 

 

 

1,444,429

 

Same-store gallons sold

 

(0.6

)%

 

 

%

 

 

(0.1

)%

 

 

0.2

%

Fuel gross profit (in thousands)

$

312,252

 

 

$

308,835

 

 

$

626,800

 

 

$

605,813

 

Fuel margin (cents per gallon, excluding credit card fees)

40.2

 ¢

 

42.3

 ¢

 

40.5

 ¢

 

41.9

 ¢

For the quarter, total fuel gallons sold increased 6.2% compared to the prior year primarily due to the store count increase, while same-store gallons were down 0.6% versus the prior year. The Company’s total fuel gross profit was up 1.1% versus the prior year. The Company sold $4.9 million in renewable fuel credits (RINs) in the second quarter, a decrease of $3.5 million from the same quarter in the prior year.

Operating Expenses

 

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Operating expenses (in thousands)

$

609,679

 

 

$

579,703

 

 

$

1,219,153

 

 

$

1,140,558

 

Credit card fees (in thousands)

$

62,275

 

 

$

62,917

 

 

$

126,084

 

 

$

123,902

 

Same-store operating expenses excluding credit card fees

 

2.3

%

 

 

2.1

%

 

 

1.5

%

 

 

2.6

%

Operating expenses increased approximately 5% during the second quarter. Operating 93 more stores than prior year accounted for approximately 4% of the increase. Same-store employee expense contributed to approximately 1% of the increase, as the increases in labor rates were partially offset by a reduction in same-store labor hours.

Expansion

 

Store Count

April 30, 2024

2,658

 

New store construction

18

 

Acquisitions

18

 

Closed

(9

)

October 31, 2024

2,685

 

_________________

2 Fuel category does not include wholesale fuel activity, which is included in Other.

Liquidity

At October 31, 2024, the Company had approximately $1.25 billion in available liquidity, consisting of approximately $352 million in cash and cash equivalents on hand and approximately $900 million in available borrowing capacity on existing lines of credit. The liquidity calculation excludes the impact of the restricted cash included within long-term assets as of October 31, 2024. The restricted cash relates to cash held in a funding account for the acquisition of Fikes, which closed on November 1, 2024, subsequent to quarter end.

Share Repurchase

During the second quarter, the Company did not repurchase any shares. The Company has approximately $295 million remaining under its existing share repurchase authorization.

Dividend

At its December meeting, the Board of Directors approved a quarterly dividend of $0.50 per share. The dividend is payable February 17, 2025, to shareholders of record on February 3, 2025.

Fiscal 2025 Outlook

Casey’s is updating the 2025 outlook primarily due to the acquisition of Fikes, which closed on November 1, 2024.

For the second half of fiscal 2025 specifically related to the Fikes transaction: Casey’s expects to incur an additional $15 to $20 million in one-time deal and integration costs, primarily in the third quarter. EBITDA contribution from Fikes is expected to be modestly dilutive in the third quarter, primarily due to the transaction and integration costs previously mentioned. EBITDA contribution from Fikes is expected to be modestly accretive in the fourth quarter. Interest expense will be approximately $35 million higher than the original outlook due to the financing of the transaction.

For Casey’s total fiscal 2025 year outlook including the impact of the Fikes acquisition: EBITDA is expected to increase at least 10%. Total operating expenses are expected to increase 11% to 13% for the fiscal year, including approximately $25 to $30 million in one-time deal and integration costs, while same-store operating expense excluding credit card fees are expected to only increase 2% for the year. Net interest expense is expected to be approximately $90 million for the year. Depreciation and amortization is expected to be approximately $410 million and the purchase of property and equipment is expected to be approximately $550 million. The tax rate is expected to be approximately 23% to 25% for the fiscal year.

Casey’s is not updating its outlook for the following metrics: Casey’s expects to add approximately 270 stores for the fiscal year. The Company expects inside same-store sales to increase 3% to 5% and inside margin comparable to fiscal 2024. The Company expects same-store fuel gallons sold to be between negative 1% to positive 1%.

Casey’s General Stores, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(Amounts in thousands, except share and per share amounts)

(Unaudited)

 

 

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Total revenue

$

3,946,771

 

$

4,064,400

 

$

8,044,508

 

$

7,933,651

Cost of goods sold (exclusive of depreciation and amortization, shown separately below)

 

2,988,212

 

 

3,178,839

 

 

6,130,693

 

 

6,170,336

Operating expenses

 

609,679

 

 

579,703

 

 

1,219,153

 

 

1,140,558

Depreciation and amortization

 

96,592

 

 

85,598

 

 

191,001

 

 

168,503

Interest, net

 

12,553

 

 

12,306

 

 

26,620

 

 

24,801

Income before income taxes

 

239,735

 

 

207,954

 

 

477,041

 

 

429,453

Federal and state income taxes

 

58,817

 

 

49,172

 

 

115,925

 

 

101,434

Net income

$

180,918

 

$

158,782

 

$

361,116

 

$

328,019

Net income per common share

 

 

 

 

 

 

 

Basic

$

4.87

 

$

4.27

 

$

9.73

 

$

8.80

Diluted

$

4.85

 

$

4.24

 

$

9.68

 

$

8.76

Basic weighted average shares

 

37,124,541

 

 

37,227,932

 

 

37,105,886

 

 

37,264,442

Plus effect of stock compensation

 

186,938

 

 

203,143

 

 

202,392

 

 

187,811

Diluted weighted average shares

 

37,311,479

 

 

37,431,075

 

 

37,308,278

 

 

37,452,253

Casey’s General Stores, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Dollars in thousands)

(Unaudited)

 

 

October 31, 2024

 

April 30, 2024

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

351,723

 

$

206,482

Receivables

 

156,407

 

 

151,793

Inventories

 

432,268

 

 

428,722

Prepaid and other current assets

 

38,296

 

 

25,791

Income taxes receivable

 

 

 

17,066

Total current assets

 

978,694

 

 

829,854

Restricted cash

 

1,160,118

 

 

Other assets, net of amortization

 

192,704

 

 

195,559

Goodwill

 

657,529

 

 

652,663

Property and equipment, net of accumulated depreciation of $2,981,245 at October 31, 2024 and $2,883,925 at April 30, 2024

 

4,736,525

 

 

4,669,357

Total assets

$

7,725,570

 

$

6,347,433

Liabilities and Shareholders’ Equity

 

 

 

Current liabilities

 

 

 

Current maturities of long-term debt and finance lease obligations

$

245,558

 

$

53,181

Accounts payable

 

573,320

 

 

569,527

Accrued expenses

 

296,374

 

 

330,758

Income taxes payable

 

1,284

 

 

Total current liabilities

 

1,116,536

 

 

953,466

Long-term debt and finance lease obligations, net of current maturities

 

2,461,922

 

 

1,582,758

Deferred income taxes

 

608,904

 

 

596,850

Insurance accruals, net of current portion

 

30,227

 

 

30,046

Other long-term liabilities

 

170,535

 

 

168,932

Total liabilities

 

4,388,124

 

 

3,332,052

Total shareholders’ equity

 

3,337,446

 

 

3,015,381

Total liabilities and shareholders’ equity

$

7,725,570

 

$

6,347,433

Casey’s General Stores, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

(Unaudited)

 

 

Six months ended October 31,

 

2024

 

2023

Cash flows from operating activities:

 

 

 

Net income

$

361,116

 

 

$

328,019

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

191,001

 

 

 

168,503

 

Amortization of debt issuance costs

 

555

 

 

 

555

 

Change in excess replacement cost over LIFO inventory valuation

 

6,398

 

 

 

7,946

 

Share-based compensation

 

23,645

 

 

 

19,485

 

Loss (gain) on disposal of assets and impairment charges

 

4,422

 

 

 

(232

)

Deferred income taxes

 

12,054

 

 

 

39,353

 

Changes in assets and liabilities:

 

 

 

Receivables

 

(855

)

 

 

(21,897

)

Inventories

 

(8,723

)

 

 

(44,714

)

Prepaid and other current assets

 

(12,505

)

 

 

(10,693

)

Accounts payable

 

(9,902

)

 

 

(10,400

)

Accrued expenses

 

(36,228

)

 

 

(20,925

)

Income taxes

 

20,780

 

 

 

21,992

 

Other, net

 

299

 

 

 

4,788

 

Net cash provided by operating activities

 

552,057

 

 

 

481,780

 

Cash flows from investing activities:

 

 

 

Purchase of property and equipment

 

(211,226

)

 

 

(175,955

)

Payments for acquisition of businesses, net of cash acquired

 

(46,341

)

 

 

(139,359

)

Proceeds from sales of assets

 

11,720

 

 

 

8,291

 

Net cash used in investing activities

 

(245,847

)

 

 

(307,023

)

Cash flows from financing activities:

 

 

 

Proceeds from long-term debt

 

1,100,000

 

 

 

 

Payments of long-term debt and finance lease obligations

 

(34,637

)

 

 

(35,135

)

Payments of debt issuance costs

 

(5,191

)

 

 

 

Payments of cash dividends

 

(35,179

)

 

 

(30,988

)

Repurchase of common stock and payment of related excise taxes

 

(734

)

 

 

(59,491

)

Tax withholdings on employee share-based awards

 

(25,110

)

 

 

(18,121

)

Net cash provided by (used) in financing activities

 

999,149

 

 

 

(143,735

)

 

Net increase in cash, cash equivalents and restricted cash

 

1,305,359

 

 

 

31,022

 

Cash and cash equivalents at beginning of the period

 

206,482

 

 

 

378,869

 

Cash, cash equivalents and restricted cash at end of the period

$

1,511,841

 

 

$

409,891

 

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

Six months ended October 31,

 

2024

 

2023

Cash and cash equivalents

$

351,723

 

$

409,891

Restricted cash

 

1,160,118

 

 

Total cash, cash equivalents and restricted cash shown in the statement of cash flows

$

1,511,841

 

$

409,891

SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION

 

 

Six months ended October 31,

 

2024

 

2023

Cash paid during the period for:

 

 

 

Interest, net of amount capitalized

$

33,516

 

$

31,429

Income taxes, net

 

82,507

 

 

36,037

Noncash investing and financing activities:

 

 

 

Purchased property and equipment in accounts payable

 

59,312

 

 

78,684

Right-of-use assets obtained in exchange for new finance lease liabilities

 

11,210

 

 

11,216

Right-of-use assets obtained in exchange for new operating lease liabilities

 

8,273

Summary by Category (Amounts in thousands)

Three Months Ended October 31, 2024

Prepared Food

& Dispensed

Beverage

 

Grocery &

General

Merchandise

 

Fuel

 

Other

 

Total

Revenue

$

417,827

 

 

$

1,049,697

 

 

$

2,414,632

 

 

$

64,615

 

 

$

3,946,771

 

Gross profit

$

245,458

 

 

$

374,193

 

 

$

312,252

 

 

$

26,656

 

 

$

958,559

 

 

 

58.7

%

 

 

35.6

%

 

 

12.9

%

 

 

41.3

%

 

 

24.3

%

Fuel gallons sold

 

 

 

 

 

775,914

 

 

 

 

 

Three Months Ended October 31, 2023

 

 

 

 

 

 

 

 

 

Revenue

$

382,481

 

 

$

964,430

 

 

$

2,646,478

 

 

$

71,011

 

 

$

4,064,400

 

Gross profit

$

225,664

 

 

$

327,600

 

 

$

308,835

 

 

$

23,462

 

 

$

885,561

 

 

 

59.0

%

 

 

34.0

%

 

 

11.7

%

 

 

33.0

%

 

 

21.8

%

Fuel gallons sold

 

 

 

 

 

730,439

 

 

 

 

 

Summary by Category (Amounts in thousands)

Six Months Ended October 31, 2024

Prepared Food

& Dispensed

Beverage

 

Grocery &

General

Merchandise

 

Fuel

 

Other

 

Total

Revenue

$

822,956

 

 

$

2,118,675

 

 

$

4,970,274

 

 

$

132,603

 

 

$

8,044,508

 

Gross profit

$

481,499

 

 

$

752,474

 

 

$

626,800

 

 

$

53,042

 

 

$

1,913,815

 

 

 

58.5

%

 

 

35.5

%

 

 

12.6

%

 

 

40.0

%

 

 

23.8

%

Fuel gallons sold

 

 

 

 

 

1,548,450

 

 

 

 

 

Six Months Ended October 31, 2023

 

 

 

 

 

 

 

 

 

Revenue

$

755,294

 

 

$

1,961,366

 

 

$

5,073,811

 

 

$

143,180

 

 

$

7,933,651

 

Gross profit

$

442,525

 

 

$

667,173

 

 

$

605,813

 

 

$

47,804

 

 

$

1,763,315

 

 

 

58.6

%

 

 

34.0

%

 

 

11.9

%

 

 

33.4

%

 

 

22.2

%

Fuel gallons sold

 

 

 

 

 

1,444,429

 

 

 

 

 

Prepared Food & Dispensed Beverage

 

Prepared Food & Dispensed Beverage

Same-store Sales

Margin

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

F2025

4.4

%

 

5.2

%

 

 

 

 

 

 

F2025

58.3

%

 

58.7

%

 

 

 

 

 

 

F2024

5.9

 

 

6.1

 

 

7.5

%

 

8.8

%

 

6.8

%

F2024

58.2

 

 

59.0

 

 

59.6

%

 

58.1

%

 

58.7

%

F2023

8.4

 

 

10.5

 

 

5.0

 

 

4.9

 

 

7.1

 

F2023

55.6

 

 

56.7

 

 

57.3

 

 

56.8

 

 

56.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grocery & General Merchandise

 

Grocery & General Merchandise

Same-store Sales

Margin

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

F2025

1.6

%

 

3.6

%

 

 

 

 

 

 

F2025

35.4

%

 

35.6

%

 

 

 

 

 

 

F2024

5.2

 

 

1.7

 

 

2.8

%

 

4.3

%

 

3.5

%

F2024

34.1

 

 

34.0

 

 

33.9

%

 

34.4

%

 

34.1

%

F2023

5.5

 

 

6.9

 

 

5.8

 

 

7.1

 

 

6.3

 

F2023

33.9

 

 

33.3

 

 

34.0

 

 

33.0

 

 

33.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fuel Gallons

 

Fuel Margin

Same-store Sales

(Cents per gallon, excluding credit card fees)

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

Year

F2025

0.7

%

 

(0.6

)%

 

 

 

 

 

 

 

 

 

F2025

40.7

¢

 

40.2

¢

 

 

 

 

 

 

F2024

0.4

 

 

 

 

(0.4

)%

 

0.9

%

 

0.1

%

F2024

41.6

 

42.3

 

37.3

¢

 

36.5

¢

 

39.5

¢

F2023

(2.3

)

 

0.3

 

 

(0.5

)

 

 

 

(0.8

)

F2023

44.7

 

40.5

 

40.7

 

34.6

 

40.2

RECONCILIATION OF NET INCOME TO EBITDA

We define EBITDA as net income before net interest expense, income taxes, depreciation and amortization. EBITDA is not considered to be a GAAP measure, and should not be considered as a substitute for net income, cash flows from operating activities or other income or cash flow statement data. This measure has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. We strongly encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We believe EBITDA is useful to investors in evaluating our operating performance because securities analysts and other interested parties use this calculation as a measure of financial performance and debt service capabilities, and it is regularly used by management for internal purposes including our capital budgeting process, evaluating acquisition targets, assessing performance, and awarding incentive compensation.

Because non-GAAP financial measures are not standardized, EBITDA, as defined by us, may not be comparable to similarly titled measures reported by other companies. It therefore may not be possible to compare our use of this non-GAAP financial measure with those used by other companies.

The following table contains a reconciliation of net income to EBITDA for the three and six months ended October 31, 2024 and 2023:

(in thousands)

Three Months Ended October 31,

 

Six Months Ended October 31,

 

2024

 

2023

 

2024

 

2023

Net income

$

180,918

 

$

158,782

 

$

361,116

 

$

328,019

Interest, net

 

12,553

 

 

12,306

 

 

26,620

 

 

24,801

Federal and state income taxes

 

58,817

 

 

49,172

 

 

115,925

 

 

101,434

Depreciation and amortization

 

96,592

 

 

85,598

 

 

191,001

 

 

168,503

EBITDA

$

348,880

 

$

305,858

 

$

694,662

 

$

622,757

NOTES:

  • Gross Profit is defined as revenue less cost of goods sold (exclusive of depreciation and amortization)

  • Inside is defined as the combination of grocery and general merchandise and prepared food and dispensed beverage

This release contains statements that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to the potential impact the Fikes transaction, expectations for future periods, possible or assumed future results of operations, financial conditions, liquidity and related sources or needs, business and/or integration strategies, plans and synergies, supply chain, growth opportunities, performance at our stores. There are a number of known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from any results expressed or implied by these forward-looking statements, including but not limited to the execution of our strategic plan, the integration and financial performance of acquired stores, wholesale fuel, inventory and ingredient costs, distribution challenges and disruptions, the impact and duration of the conflict in Ukraine or other geopolitical disruptions, as well as other risks, uncertainties and factors which are described in the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as filed with the Securities and Exchange Commission and available on our website. Any forward-looking statements contained in this release represent our current views as of the date of this release with respect to future events, and Casey’s disclaims any intention or obligation to update or revise any forward-looking statements in the release whether as a result of new information, future events, or otherwise.

Corporate information is available at this website: https://www.caseys.com. Earnings will be reported during a conference call on December 10, 2024. The call will be broadcast live over the Internet at 7:30 a.m. CDT. To access the call, go to the Events and Presentations section of our website at https://investor.caseys.com/events-and-presentations/default.aspx. No access code is required. A webcast replay of the call will remain available in an archived format on the Events and Presentations section of our website at https://investor.caseys.com/events-and-presentations/default.aspx for one year after the call.

Investor Relations Contact:

Brian Johnson (515) 446-6587

Media Relations Contact:

Katie Petru (515) 446-6772

KEYWORDS: Iowa United States North America

INDUSTRY KEYWORDS: Retail Restaurant/Bar Convenience Store Oil/Gas Tobacco Energy Food/Beverage

MEDIA:

Healthpeak Properties Extends Its $3 Billion Revolving Credit Facility

Healthpeak Properties Extends Its $3 Billion Revolving Credit Facility

DENVER–(BUSINESS WIRE)–
Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced today that its operating partnership has amended and extended its $3 billion revolving credit facility (“Credit Facility”), as well as made conforming amendments to its outstanding term loans in connection with the Credit Facility.

“We appreciate the strong support of our lender group who offered to provide over $5 billion of total commitments for this transaction. This successful transaction is a testament to the strength of our balance sheet, and more importantly, supports Healthpeak’s growth initiatives and ongoing commitment to create long-term value for our shareholders,” said Peter Scott, Chief Financial Officer.

The Credit Facility will initially mature in January 2029 and can be extended pursuant to two six-month extension options, subject to certain conditions. Based on Healthpeak’s current credit ratings, the Credit Facility bears interest at a rate per annum equal to SOFR plus 77.5 basis points, and carries a facility fee on the entire revolving commitment of 15 basis points per annum.

The Credit Facility was arranged by BofA Securities, Inc., JPMorgan Chase Bank, N.A., and Wells Fargo Securities, LLC. Bank of America, N.A. is serving as the Administrative Agent, and JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association acted as Co-Syndication Agents for the Credit Facility. Bank of America, N.A. and Credit Agricole Corporate and Investment Bank are serving as Structuring Sustainability Agents.

ABOUT HEALTHPEAK PROPERTIES

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate focused on healthcare discovery and delivery. For more information regarding Healthpeak, visit www.healthpeak.com.

Andrew Johns, CFA

Senior Vice President – Investor Relations

720-428-5400

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance Health Professional Services REIT Other Construction & Property Other Health

MEDIA:

Logo
Logo